Coquí RadioPharmaceuticals Corporation

Coquí Pharma is working toward becoming the first U.S. commercial supplier of the lifesaving radioisotope Molybdenum-99 (Mo-99), which is used in 20 million procedures each year in the U.S. Because of a very short lifespan, the isotope needs to be used in patients quickly after it is created. With the closest producer of this isotope closing the doors of their Canadian facility, Gresham Smith provided design and engineering services for the new 250,000-square-foot Coquí RadioPharmaceuticals Corp. medical isotope facility to support needs in North America. The new facility utilizes sustainable design, construction and operational practices to support successful domestic production of the isotope.

The design features a corporate headquarters and a state-of-the-art isotope production facility. The project will support the company’s unique production needs with highly tailored process-driven design, while also serving as an inspiring, modern and sustainable landmark. The design supports Coquí Pharma’s goal to operate on a minimum energy consumption rate with limited carbon dioxide emissions by mitigating solar exposure and enhancing the control of daylight throughout the building. Water efficiency is also a feature, with the most effective use of water inside the facility as well as for the lush, tropical landscaping to be employed.